SCHEMBL15937148

SCHEMBL15937148

CC(C)CN1CC2(CCCN2C(=O)OC(C)(C)C)C1=O

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.59
GRIN2C Q14957 1/20 0.59
JAK3 P52333 2/20 0.34
PIK3CD O00329 3/20 0.33
HSD11B1 P28845 1/20 0.33
CYP2D6 P10635 3/20 0.33
USP2 O75604 2/20 0.33
CYP3A4 P08684 2/20 0.33
ALOX15 P16050 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
POLB P06746 1/20 0.32
CTSK P43235 1/20 0.32
CNR2 P34972 1/20 0.32
CDK4 P11802 1/20 0.32
NPC1L1 Q9UHC9 1/20 0.31
NAMPT P43490 1/20 0.31
USP30 Q70CQ3 1/20 0.31
SPR P35270 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15937072 0.84 GRIN2B (0.55) GRIN2BGRIN2CJAK3CTSKCDK4
SCHEMBL15937196 0.82 GRIN2B (0.53) GRIN2BGRIN2CJAK3CYP2D6CYP3A4
SCHEMBL15937080 0.81 GRIN2B (0.52) GRIN2BGRIN2CJAK3NPC1L1
SCHEMBL19501064 0.81 GRIN2B (0.41) GRIN2BGRIN2CCTSK
SCHEMBL17356206 0.81 GRIN2B (0.41) GRIN2BGRIN2CCTSK
SCHEMBL21466075 0.79 GRIN2B (0.63) GRIN2BGRIN2CJAK3USP2CTSK
SCHEMBL14719073 0.79 GRIN2B (0.50) GRIN2BGRIN2CCYP2D6CYP3A4NPC1L1
SCHEMBL25852386 0.79 GRIN2B (0.51) GRIN2BGRIN2CJAK3USP2CTSK
SCHEMBL17352426 0.78 GRIN2B (0.49) GRIN2BGRIN2CJAK3POLBCNR2
SCHEMBL29650540 0.78 GRIN2B (0.54) GRIN2BGRIN2CJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10273239-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2019-04-30 US disclosed
US-20180179217-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2018-06-28 US disclosed
US-20180179217-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2018-06-28 US disclosed
US-9758525-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2017-09-12 US disclosed
US-9758525-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2017-09-12 US disclosed
US-9758525-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2017-09-12 US disclosed
US-20150368253-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2015-12-24 US disclosed
US-20150368253-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2015-12-24 US disclosed
US-20150368253-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2015-12-24 US disclosed
WO-2014120786-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF NAUREX, INC. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368253-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A GRIN2B 5/4885GRIN2C 4/4885JAK3 4606/4885
US-10273239-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A GRIN2B 5/4885GRIN2C 4/4885JAK3 4606/4885
US-20180179217-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A GRIN2B 5/4885GRIN2C 4/4885JAK3 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.